Clinical trials: SARS-COV2 Virus
SARS-CoV-2 Infection
A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19)
This is a Phase 2, randomized, observer-blinded study evaluating the safety and immunogenicity of SARS-CoV-2 with Matrix-M™ Adjuvant in people living with human immunodeficiency virus (HIV) (PLWH) and HIV- negative adults…
- Trial name
- COVID-19 (NCT05112848)
- Testing
- NVX-CoV2373
- Where
- 7 sites in South Africa
- Volunteers
- 384 people
- Sponsor
- Novavax
COVID-19
Effectiveness of COVID-19 Vaccine for Prevention of COVID-19 in the Dominican Republic
This study is a multisite ,grouped test-negative case-control , phase Ⅳ clinical trial of an inactivated SARS-CoV-2 vaccine (CoronaVac) manufactured by Sinovac Research and Development Co., Ltd.The purpose of this study is to…
- Trial name
- NCT04974164
- Testing
- Inactivated COVID-19 Vaccine
- Where
- 10 sites in Dominican Republic
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
COVID-19
Australian Phase 2b Study to Assess Effect of Dose Interval on Spikogen Covid-19 Vaccine
A study to assess the effect of varying the time interval between doses on the immunogenicity of an adjuvanted recombinant spike protein Covid-19 vaccine (Spikogen/Covax-19)
- Trial name
- NCT05148871
- Testing
- Spikogen/Covax-19
- Where
- Australia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
COVID-19, Vaccine-Preventable Diseases
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
To assess the impact of reactogenicity among health care workers and first responders receiving an updated 2024-25 Novavax COVID-19 vaccine as compared with those receiving an updated 2024-25 Pfizer-BioNTech mRNA COVID-19 vaccine
- Conditions
- COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection
- Trial name
- SHIELD (NCT06633835)
- Testing
- protein subunit: Novavax COVID-19 vaccine, Pfizer mRNA COVID-19 vaccine
- Where
- United States
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Novavax
SARS-CoV-2 Infection, COVID-19
A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals
The purpose of this clinical trial is to learn about the safety, tolerability and immunogenicity of BNT162b RNA-based SARS-CoV-2 vaccine candidates in adults to prevent COVID-19.
- Trial name
- NCT05472038
- Testing
- BNT162b5 Bivalent (WT/OMI BA.2), BNT162b2 Bivalent (WT/OMI BA.1), BNT162b2 Bivalent (WT/OMI BA.4/BA.5)
- Where
- 31 sites in United States
- Volunteers
- 1,453 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19 SARS-CoV-2 Infection
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease.
- Trial name
- NCT06679140
- Testing
- ibuzatrelvir
- Where
- 256 sites in United States, Argentina and 17 more
- Volunteers
- 2,330 people
- Sponsor
- Pfizer
COVID-19, Vaccine Reaction
The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001
The goal of this clinical trial is to assess the immunogenicity and safety following a heterologous booster dose of recombinant SARS-CoV-2 vaccine (CHO cell) LYB001 in adults 18-59 years of age completed two- or three-dose…
- Trial name
- NCT05928455
- Testing
- LYB001, CoronaVac
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
Immunization Against COVID-19
Efficacy and Safety of Ergoferon for COVID-19 Prevention During Vaccination Against SARS-CoV-2
The multicenter, double-blind, placebo-controlled, parallel-group, randomized clinical trial. The objective of this study is to evaluate the efficacy and safety of Ergoferon as a non-specific preventive medicine for COVID-19 in…
- Trial name
- NCT05069649
- Testing
- Ergoferon
- Where
- 33 sites in Russia
- Volunteers
- 1,057 people
- Sponsor
- Materia Medica Holding
Covid19 Vaccine
A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults
The purpose of this study is to assess the safety and immunogenicity of MVC-COV1901 vaccine in two different dose forms in participants who are generally healthy or with stable pre-existing health conditions.
- Trial name
- NCT04822025
- Testing
- MVC-COV1901 (High-Dose), MVC-COV1901(Mid-Dose)
- Where
- 4 sites in Taiwan
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Medigen Vaccine Biologics Corp.
Influenza A, Influenza Type B
FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol
The goal of this observational study is to compare the FINDER FLU A/B, RSV, SARS-CoV-2 Test to an FDA-cleared device. The study will utilize prospectively collected de-identified nasopharyngeal samples obtained from both…
- Conditions
- Influenza A, Influenza Type B, SARS CoV 2 Infection, RSV Infection
- Trial name
- NCT05928507
- Testing
- Diagnostic Test for identification of influenzas A, influenzas B, RSV and SARS-CoV-2 infections
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Baebies, Inc.
SARS-CoV-2
Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.
Hyper-inflammation, caused by a cytokine storm resulting from an exaggerated response of the immune system in the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is considered to represent one of the…
- Trial name
- NCT04324021
- Testing
- Emapalumab, Anakinra
- Where
- 12 sites in United States, Italy
- Volunteers
- 16 people
- Sponsor
- Swedish Orphan Biovitrum
Infections, Respiratory, Virus Diseases
A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults
Originally, the study was planned to include two parts, i.e., Part A and Part B, however Part B was cancelled due to changes in the overall clinical development plan.
- Conditions
- Infections, Respiratory, Virus Diseases, Infection Viral, Vaccine Adverse Reaction
- Trial name
- NCT04380701
- Testing
- BNT162a1, BNT162b1, BNT162b2
- Where
- 5 sites in Germany
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19
A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults
This study will evaluate the reactogenicity, safety, and immune response of Flu Seasonal/SARS-CoV-2 mRNA (mRNA Flu/COVID-19) combination vaccine.
- Trial name
- NCT06680375
- Testing
- Flu Seasonal /SARS-CoV-2 mRNA Dose 1, Flu Seasonal /SARS-CoV-2 mRNA Dose 2, Flu Seasonal mRNA
- Where
- 9 sites in United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
Q-POC SARS-CoV-2 Assay COVID-19 Clinical Evaluation
Q-POC SARS-CoV-2 moderate complexity PCR test performance evaluation
- Trial name
- NCT05614011
- Testing
- RT-PCR Test, Real-time PCR Test
- Where
- 3 sites in United States
- Volunteers
- 877 people
- Sponsor
- QuantuMDx Group Ltd
COVID-19
Immunogenicity and Safety Study of SARS-CoV-2 DNA Vaccine (ICCOV)
This is an open-labeled, no placebo, Phase IIa clinical trial. The purpose of this study is to evaluate the immunogenicity and safety of one booster vaccine dose of SARS-CoV-2 DNA Vaccine (ICCOV) in adults aged 18 to 75 years who…
- Trial name
- NCT05904054
- Testing
- SARS-CoV-2 DNA Vaccine (ICCOV)
- Where
- Hong Kong
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Immuno Cure 3 Limited
SARS-CoV-2 Infection
A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine
To evaluate the immunogenicity and safety of a COVID-19 mRNA vaccine (ZSVG-02-O) in a healthy population aged 18 years and older.
- Trial name
- NCT06113731
- Testing
- COVID-19 mRNA Vaccine (ZSVG-02-O), COVID-19 Vaccine (Vero Cell) ,Inactivated
- Where
- 2 sites in China
- Volunteers
- 980 people, healthy volunteers welcome
- Sponsor
- CNBG-Virogin Biotech (Shanghai) Ltd.
Respiratory Viral Infection, Respiratory Tract Diseases
PREvent Viral Exposure and Transmission Study: a COVID-19 (SARS-CoV-2) PEP Study (PREVENT)
This is an open label controlled household-randomised trial designed to evaluate the efficacy of RESP301 alongside standard of care ("SOC") versus SOC alone.
- Conditions
- Respiratory Viral Infection, Respiratory Tract Diseases, COVID-19 Respiratory Infection
- Trial name
- PREVENT (NCT04842331)
- Testing
- RESP301 (a nitric oxide generating solution), Standard of Care (SOC)
- Where
- United Kingdom
- Sponsor
- Thirty Respiratory Limited
COVID-19
Losmapimod Safety and Efficacy in COVID-19
The therapeutic hypothesis for the use of losmapimod in COVID-19 disease is that increased mortality and severe disease is caused by p38 mitogen-activated protein kinase (MAPK)-mediated exaggerated acute inflammatory response…
- Trial name
- LOSVID (NCT04511819)
- Testing
- Losmapimod oral tablet
- Where
- 16 sites in United States, Brazil and 2 more
- Volunteers
- 52 people
- Sponsor
- Fulcrum Therapeutics
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines
This study is a phase Ⅱ clinical trial to evaluate the safety and immunogenicity of SCTV01E-2 in people of different ages who had been vaccinated with COVID-19 vaccines.
- Trial name
- NCT05933512
- Testing
- SCTV01E-2, SCTV01E
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Covid19
Intravenous Infusion of CAP-1002 in Patients With COVID-19
This is a randomized, double-blind, placebo-controlled, Pilot, Phase 2 Exploratory study that will enroll subjects with a clinical diagnosis of COVID-19 confirmed by laboratory testing and who are in severe or critical condition…
- Trial name
- INSPIRE (NCT04623671)
- Testing
- CAP-1002
- Where
- 4 sites in United States
- Volunteers
- 55 people
- Sponsor
- Capricor Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.